Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse generics. Learn why TAK stock is a buy.

The pharmaceutical company is evaluating all options to increase its presence in therapy areas, including in-licensing ...

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...

Q4 2024 Earnings Call Transcript May 9, 2025 Christopher O’Reilly: Thank you very much for taking time out of their busy schedule to join our earnings announcement for FY ’24 for Takeda. I’m the ...

Japanese pharma major Takeda (TYO: 4502) announced that the US Food and Drug Administration (FDA) has accepted for priority ...

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

Investors might want to bet on Takeda Pharmaceutical Co. (TAK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO Christophe Weber said Thursday, with the money going toward both manufacturing ...